Raras
Buscar doenças, sintomas, genes...
Dificuldade respiratória aguda neonatal por deficiência de SP-B
ORPHA:217563CID-10 · P28.0CID-11 · CB04.2OMIM 265120DOENÇA RARA

Vitamina D faz parte de um grupo de secosteroides solúveis em gordura responsáveis por aumentar a absorção intestinal de cálcio, magnésio e fosfato e por muitos outros efeitos biológicos. Em humanos, os compostos mais importantes neste grupo são a vitamina D3 (também conhecida como colecalciferol) e a vitamina D2 (ergocalciferol).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Síndrome de Dificuldade Respiratória Aguda Neonatal por Deficiência de SP-B é uma doença autossômica recessiva rara que causa opacidades e infiltrados pulmonares, levando a desconforto respiratório grave no recém-nascido.

Pesquisas ativas
2 ensaios
6 total registrados no ClinicalTrials.gov
Publicações científicas
70 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Neonatal
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: P28.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫁
Pulmão
16 sintomas
❤️
Coração
1 sintomas
😀
Face
1 sintomas
📏
Crescimento
1 sintomas

+ 7 sintomas em outras categorias

Características mais comuns

100%prev.
Acúmulo intra-alveolar de fosfolipídios
Frequência: 5/5
100%prev.
Início neonatal
Frequência: 5/5
90%prev.
Taquipneia
Muito frequente (99-80%)
90%prev.
Morfologia intersticial pulmonar anormal
Muito frequente (99-80%)
90%prev.
Desconforto respiratório neonatal
Muito frequente (99-80%)
80%prev.
Opacificação em vidro fosco na TC de alta resolução pulmonar
Frequência: 12/15
26sintomas
Muito frequente (7)
Frequente (7)
Ocasional (4)
Sem dados (8)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 26 características clínicas mais associadas, ordenadas por frequência.

Acúmulo intra-alveolar de fosfolipídiosIntraalveolar phospholipid accumulation
Frequência: 5/5100%
Início neonatalNeonatal onset
Frequência: 5/5100%
TaquipneiaTachypnea
Muito frequente (99-80%)90%
Morfologia intersticial pulmonar anormalAbnormal pulmonary interstitial morphology
Muito frequente (99-80%)90%
Desconforto respiratório neonatalNeonatal respiratory distress
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico70PubMed
Últimos 10 anos66publicações
Pico202512 papers
Linha do tempo
2026Hoje · 2026🧪 1976Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive.

ABCA3Phospholipid-transporting ATPase ABCA3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the ATP-dependent transport of phospholipids such as phosphatidylcholine and phosphoglycerol from the cytoplasm into the lumen side of lamellar bodies, in turn participates in the lamellar bodies biogenesis and homeostasis of pulmonary surfactant (PubMed:16959783, PubMed:17574245, PubMed:27177387, PubMed:28887056, PubMed:31473345). Transports preferentially phosphatidylcholine containing short acyl chains (PubMed:27177387). In addition plays a role as an efflux transporter of miltefosi

LOCALIZAÇÃO

Endosome, multivesicular body membraneCytoplasmic vesicle membraneLate endosome membraneLysosome membrane

VIAS BIOLÓGICAS (2)
Surfactant metabolismABC transporters in lipid homeostasis
MECANISMO DE DOENÇA

Pulmonary surfactant metabolism dysfunction 3

A rare lung disorder due to impaired surfactant homeostasis. It is characterized by alveolar filling with floccular material that stains positive using the periodic acid-Schiff method and is derived from surfactant phospholipids and protein components. Excessive lipoproteins accumulation in the alveoli results in severe respiratory distress.

INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (4)
interstitial lung disease due to ABCA3 deficiencysurfactant metabolism dysfunction, pulmonary, 1idiopathic pulmonary fibrosispediatric acute respiratory distress syndrome
HGNC:33UniProt:Q99758
SFTPBPulmonary surfactant-associated protein BDisease-causing germline mutation(s) (loss of function) inTolerante
FUNÇÃO

Pulmonary surfactant-associated proteins promote alveolar stability by lowering the surface tension at the air-liquid interface in the peripheral air spaces. SP-B increases the collapse pressure of palmitic acid to nearly 70 millinewtons per meter

LOCALIZAÇÃO

Secreted, extracellular space, surface film

VIAS BIOLÓGICAS (3)
Surfactant metabolismDefective CSF2RB causes SMDP5Defective CSF2RA causes SMDP4
MECANISMO DE DOENÇA

Pulmonary surfactant metabolism dysfunction 1

A rare lung disorder due to impaired surfactant homeostasis. It is characterized by alveolar filling with floccular material that stains positive using the periodic acid-Schiff method and is derived from surfactant phospholipids and protein components. Excessive lipoproteins accumulation in the alveoli results in severe respiratory distress.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pulmão
3425.7 TPM
Tireoide
37.6 TPM
Rim - Córtex
1.1 TPM
Cerebelo
0.5 TPM
Testículo
0.5 TPM
OUTRAS DOENÇAS (2)
surfactant metabolism dysfunction, pulmonary, 1pediatric acute respiratory distress syndrome
HGNC:10801UniProt:P07988

Variantes genéticas (ClinVar)

290 variantes patogênicas registradas no ClinVar.

🧬 SFTPB: NM_000542.5(SFTPB):c.439C>T (p.Gln147Ter) ()
🧬 SFTPB: NM_000542.5(SFTPB):c.1029_1031dup (p.Pro344_Gln345insPro) ()
🧬 SFTPB: GRCh37/hg19 2p11.2(chr2:85860694-85917890)x1 ()
🧬 SFTPB: NM_000542.5(SFTPB):c.195+1G>A ()
🧬 SFTPB: NM_000542.5(SFTPB):c.195+4A>G ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico4
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 4 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Dificuldade respiratória aguda neonatal por deficiência de SP-B

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

6 ensaios clínicos encontrados, 2 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
67 papers (10 anos)
#1

Neonatal hypoxic-ischemic encephalopathy online registry in Shenzhen: protocol for a multicentre, prospective, open, observational cohort study.

BMJ open2026 Mar 18

Hypoxic-ischaemic encephalopathy (HIE), a leading cause of neurological disability in neonates, is managed with therapeutic hypothermia, yet systematic data on its aetiology and prognosis are lacking, particularly in China. Herein, our study addresses this gap by establishing a prospective registry in Shenzhen and aims to clinically characterise HIE, identify its risk factors and document its long-term outcomes. We will recruit 200 neonates with HIE from 10 hospitals in Shenzhen, China, between January 2025 and December 2028. In parallel, clinical data will be collected during hospitalisation, with supplemental referral information obtained from birth hospitals via an online, specialised HIE database. We will include HIE severity, survival status and the incidence of serious complications, such as arrhythmias, pulmonary haemorrhage, neonatal acute respiratory distress syndrome, persistent pulmonary hypertension of the newborn and disseminated intravascular coagulation, to assess key outcomes of HIE in neonates.Longitudinal follow-up is scheduled for 18, 24 and 36 months, involving assessments using physical developmental scales, video-electroencephalogram (VEEG) recordings, the Chinese version of the Bayley Infant and Toddler Developmental Scale, Fourth Edition and cranial MRI at 18 months. The primary objectives of this study are to determine survival status, track loss-to-follow-up rates and evaluate neurodevelopmental outcomes at 3 years, with the ultimate goal of enhancing our understanding of HIE risk factors, hypothermia therapy and prognosis to reduce HIE-related morbidity and disability. This study protocol has been approved by the Medical Ethics Committee of Shenzhen Children's Hospital (Ethics No. 2024096), and the findings will be disseminated through presentations at national academic conferences and publication in peer-reviewed paediatric journals. ChiCTR2400094994.

#2

High-Frequency Oscillation vs Mechanical Ventilation for Neonatal Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.

JAMA network open2026 Mar 02

Key clinical features of neonatal acute respiratory distress syndrome (NARDS) are broadly comparable to those observed in pediatric and adult ARDS; however, evidence is insufficient to recommend high-frequency oscillatory ventilation (HFOV) or conventional mechanical ventilation (CMV) as the preferred first-line therapy. To evaluate whether HFOV is superior to CMV in reducing bronchopulmonary dysplasia (BPD) and other neonatal adverse outcomes, including death, among preterm infants (≤34 weeks' gestational age) with NARDS. This single-center randomized clinical trial conducted from August 1, 2019, to December 31, 2023, enrolled preterm infants born between 25 weeks 0 days and 34 weeks 6 days of gestation with NARDS who were stabilized with CMV. Data were analyzed from October to December 2024. Participants were randomly assigned to continue CMV or transition to elective HFOV. The primary outcome was BPD, assessed using 2 definitions: definition 1, that of the 2001 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and definition 2, one based on 2019 research. Secondary outcomes included death, retinopathy of prematurity (higher than stage 2), necrotizing enterocolitis (stage 2 or higher), intraventricular hemorrhage (grade 3 or higher), air leak, and hemodynamically significant patent ductus arteriosus. Modified Poisson regression, ordinal regression, and Cox proportional hazards regression were applied for outcome risk assessment where applicable. A total of 386 preterm infants (230 male [59.6%]; mean [SD] maternal age, 29.9 [4.8] years) were randomized: 181 to elective HFOV and 205 to CMV. Overall, 154 (39.9%) and 83 (21.5%) developed BPD according definitions 1 and 2, respectively. Elective HFOV reduced the risk of BPD by 8.0% (34.3% vs 44.9%; relative risk, 0.92; 95% CI, 0.86-0.99) according to definition 1 and by 32.0% (17.1% vs 25.4%; relative risk 0.68; 95% CI, 0.45-1.00) according to definition 2 compared with CMV. No significant between-group differences were observed for death, higher than stage 2 retinopathy of prematurity, stage 2 or higher necrotizing enterocolitis, grade 3 or higher intraventricular hemorrhage, air leak, or hemodynamically significant patent ductus arteriosus. Sensitivity analysis excluding 44 participants who crossed over between treatment groups did not significantly attenuate the estimates. This randomized clinical trial found that elective HFOV reduced the incidence of BPD in preterm infants born at 34 weeks' gestation or earlier with NARDS compared with CMV. The results of this study suggest that elective HFOV is a promising strategy for preventing BPD in this high-risk population, especially the more severe forms linked to increased long-term morbidity and mortality. ClinicalTrials.gov Identifier: NCT03591796.

#3

Respiratory Management of Neonatal Acute Respiratory Distress Syndrome.

JAMA network open2026 Mar 02
#4

A Predictive Model for Moderate or Severe Neonatal Acute Respiratory Distress Syndrome in Extremely Preterm Infants with Premature Rupture of Membranes: Development and Internal Validation.

Journal of inflammation research2026

Preterm premature rupture of membranes (PROM) is a major cause of extremely preterm birth. Intrauterine infection and inflammation markedly increase the risk of neonatal acute respiratory distress syndrome (NARDS), particularly moderate or severe cases associated with poor outcomes. This study developed and validated a prediction model for moderate or severe NARDS in this population using inflammatory biomarkers. This single center retrospective cohort study included 243 extremely preterm infants with PROM from 2015 to 2024. The primary outcome was moderate or severe NARDS occurring within 72 hours after delivery, diagnosed according to Montreux criteria. Patients were grouped by NARDS severity. Predictive variables were screened using LASSO regression and incorporated into a multivariable logistic model to build a nomogram. Model performance was assessed through receiver operating characteristic curves (ROC), calibration plots and decision curve analysis (DCA). The primary outcome incidence was 20.2% (49/243). Multivariable analysis identified elevated C-reactive protein (CRP) (OR=1.04, 95% CI:1.01-1.07), decreased platelet count (OR=0.99, 95% CI:0.988-0.998), decreased albumin (OR=0.87, 95% CI:0.80-0.95), and decreased arterial pH (OR=0.01, 95% CI:0.001-0.041) as independent predictors. The nomogram integrating these four parameters demonstrated excellent discrimination with an area under the curve (AUC) of 0.824. Internal validation demonstrated good robustness (C-index=0.795). To enhance clinical translation, we developed an interactive web calculator for real time risk assessment to guide pediatricians' clinical decision making. DCA established a 30% risk threshold to inform early interventions. The validated model containing CRP, platelets, albumin and pH effectively identifies high risk PROM infants. The web based interface enables practical bedside application for early detection of critical cases. Patients with predicted probabilities reaching 30% should be considered for preventive lung protection measures. Additional multicenter studies are needed to verify wider applicability and enhance clinical implementation protocols.

#5

Newborns with ARDS originating from sepsis of extrapulmonary origin exhibit worse prognoses: findings from a multicenter study in China.

European journal of pediatrics2025 Dec 04

Research on the infection-related etiologies of neonatal acute respiratory distress syndrome (NARDS) remains limited. This study aimed to investigate mortality risk differences in NARDS attributed to distinct infection origins (sepsis of extrapulmonary origin or pulmonary infection origin). Subjects were derived from a multicenter retrospective study organized by the Jiangsu Provincial Neonatal Respiratory Failure Collaboration Network. It included neonates with NARDS who initiated invasive mechanical ventilation (IMV) within 72 h of birth. A total of 268 from 1275 NARDS cases with infectious etiologies were enrolled. Multivariate Cox regression found a significant difference in the survival prognosis (sepsis of extrapulmonary origin, adjusted hazard ratio (HR): 3.93, 95% CI 1.79-8.62, log-rank test: P < 0.001]. Further multi-model and sensitivity analysis confirmed the robustness. Between early-onset and late-onset NARDS, the subgroup analysis showed no significant differences in the mortality risk, whether it was pulmonary infection origin (HR 1.69, 95% CI 0.61-4.64) or sepsis of extrapulmonary origin (HR 0.50, 95% CI 0.17-1.51). Restricted cubic spline also exhibited that the onset time of NARDS was not related to the mortality risk. This study suggests that for sepsis of extrapulmonary origin, we should be more vigilant about the mortality risk it brings and deal with the risk factors more actively and prudently. • Limited research has systematically investigated the association between infection origin and mortality risk in neonatal acute respiratory distress syndrome (NARDS). • Our study found that sepsis of extrapulmonary origin was associated with an increased mortality risk in neonates with gestational age > 34 weeks, with robust results from multivariate Cox modeling and sensitivity analyses. • It highlights the need for heightened vigilance and proactive management of extrapulmonary sepsis-related NARDS to mitigate mortality risk in neonates.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC46 artigos no totalmostrando 66

2026

Neonatal hypoxic-ischemic encephalopathy online registry in Shenzhen: protocol for a multicentre, prospective, open, observational cohort study.

BMJ open
2026

Respiratory Management of Neonatal Acute Respiratory Distress Syndrome.

JAMA network open
2026

High-Frequency Oscillation vs Mechanical Ventilation for Neonatal Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.

JAMA network open
2026

A Predictive Model for Moderate or Severe Neonatal Acute Respiratory Distress Syndrome in Extremely Preterm Infants with Premature Rupture of Membranes: Development and Internal Validation.

Journal of inflammation research
2025

Newborns with ARDS originating from sepsis of extrapulmonary origin exhibit worse prognoses: findings from a multicenter study in China.

European journal of pediatrics
2025

The Shenzhen neonatal ARDS cohort study: a multi-omics approach to elucidating regional epidemiology, refined phenotypes, and long-term outcomes.

Frontiers in pediatrics
2025

Risk factors for mortality in neonatal ARDS: a multicenter retrospective cohort study in China.

Frontiers of medicine
2025

Inhaled nitric oxide in therapy of pediatric and neonatal acute respiratory distress syndrome: the good, the bad and the ugly.

Expert review of respiratory medicine
2025

Heliox preconditioning exerts pulmonary protection effects on neonatal acute respiratory distress syndrome by inhibiting oxidative stress and apoptosis.

Frontiers in pharmacology
2025

Szeto-Schiller 31 eases acute lung injury in neonatal mice with acute respiratory distress syndrome by mediating TXNIP expression and NLRP3 inflammasome activation.

Translational pediatrics
2025

Transcriptomic signatures of neonatal acute respiratory distress syndrome in a prospective cohort of respiratory distress.

iScience
2025

Rib-indexed quantitative lung ultrasound versus chest X-ray for lung recruitment assessment in neonates with moderate-severe ARDS on surfactant therapy combined with prone position: a prospective observational study.

European journal of pediatrics
2025

Dynamic Changes of Plasma Mitochondrial DNA in Neonates with Acute Respiratory Distress Syndrome.

Fetal and pediatric pathology
2025

Analysis of early surgical indications and related factors in neonatal necrotizing enterocolitis.

Frontiers in pediatrics
2025

Characteristics, triggers, treatments, and experimental models of neonatal acute respiratory distress syndrome.

American journal of physiology. Lung cellular and molecular physiology
2024

A nomogram for predicting neonatal acute respiratory distress syndrome in patients with neonatal pneumonia after 34 weeks of gestation.

Frontiers in pediatrics
2025

Clinical Diagnostic Value of miR-193a-5p in Neonatal Acute Respiratory Distress Syndrome and Analysis of Its Effect on Human Lung Epithelial Cells.

Fetal and pediatric pathology
2024

Critical Appraisal and Future Directions for the Association Between Albumin Levels and Neonatal Acute Respiratory Distress Syndrome in Newborn Pneumoniae [Letter].

Journal of inflammation research
2024

Association Between Albumin Levels and Neonatal Acute Respiratory Distress Syndrome in Newborn Pneumoniae.

Journal of inflammation research
2024

Endotracheal Surfactant and Budesonide Combination Therapy in Neonatal Acute Respiratory Distress Syndrome due to Late-Onset Sepsis.

Archives of Iranian medicine
2024

Lung-Gut Microbiota and Tryptophan Metabolites Changes in Neonatal Acute Respiratory Distress Syndrome.

Journal of inflammation research
2023

Prevalence and factors associated with neonatal acute respiratory distress syndrome among neonates admitted to the neonatal intensive care units of Gurage zone public hospital, South West Ethiopia.

African health sciences
2024

Inspiratory-expiratory variation of pleural line thickness in neonates with and without acute respiratory failure.

Respiratory research
2023

Development and validation of a predictive model for early diagnosis of neonatal acute respiratory distress syndrome based on the Montreux definition.

Frontiers in pediatrics
2023

Surfactant status assessment and personalized therapy for surfactant deficiency or dysfunction.

Seminars in fetal &amp; neonatal medicine
2023

Epidemiology of neonatal acute respiratory distress syndrome in a neonatal ICU: a retrospective study utilising the Montreux definition.

Singapore medical journal
2023

The perinatal period should be considered in neonatal acute respiratory distress syndrome: comparison of the Montreux definition vs. the second pediatric acute lung injury consensus conference definition.

Frontiers in pediatrics
2023

Effect of different ventilation methods combined with pulmonary surfactant on neonatal acute respiratory distress syndrome.

World journal of clinical cases
2024

Lung ultrasound score for monitoring the withdrawal of extracorporeal membrane oxygenation on neonatal acute respiratory distress syndrome.

Heart &amp; lung : the journal of critical care
2023

Protective Effect of Unfractionated Heparin on Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Neonatal Mice via the JAK2/STAT3 Signaling Pathway.

Frontiers in bioscience (Landmark edition)
2023

Effect of preterm chorioamnionitis on lung ultrasound score used to guide surfactant replacement.

Pediatric pulmonology
2023

Comparison of the Montreux definition with the Berlin definition for neonatal acute respiratory distress syndrome.

European journal of pediatrics
2023

Establishment and evaluation of nomogram for predicting intraventricular hemorrhage in neonatal acute respiratory distress syndrome.

BMC pediatrics
2022

MiR-338-3p Is a Biomarker in Neonatal Acute Respiratory Distress Syndrome (ARDS) and Has Roles in the Inflammatory Response of ARDS Cell Models.

Acta medica Okayama
2022

Expression and prognostic value of MIP-1α in neonatal acute respiratory distress syndrome.

American journal of translational research
2023

Clinical characteristics and outcomes in neonates with perinatal acute respiratory distress syndrome in China: A national, multicentre, cross-sectional study.

EClinicalMedicine
2022

Rare-variant collapsing analyses identified risk genes for neonatal acute respiratory distress syndrome.

Computational and structural biotechnology journal
2022

A prediction nomogram for neonatal acute respiratory distress syndrome in late-preterm infants and full-term infants: A retrospective study.

EClinicalMedicine
2022

Characterization of phospholipid-modified lung surfactant in vitro and in a neonatal ARDS model reveals anti-inflammatory potential and surfactant lipidome signatures.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
2022

Clinical value of serum miR-92 and miR-122 expression level combined with pulmonary ultrasound score in the prognosis of neonatal acute respiratory distress syndrome.

Journal of clinical laboratory analysis
2022

Epidemiology of Neonatal Acute Respiratory Distress Syndrome: Prospective, Multicenter, International Cohort Study.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
2022

Risk Factors and Clinical Characteristics of Neonatal Acute Respiratory Distress Syndrome Caused by Early Onset Sepsis.

Frontiers in pediatrics
2022

Management of severe neonatal respiratory distress due to vertical transmission of severe acute respiratory syndrome coronavirus 2: a case report.

Journal of medical case reports
2024

Risk Factors of Neonatal Acute Respiratory Distress Syndrome Based on the Montreux Definition in Neonates with Sepsis: A Retrospective Case-Control Study.

American journal of perinatology
2022

Lipocalin-2 silencing suppresses inflammation and oxidative stress of acute respiratory distress syndrome by ferroptosis via inhibition of MAPK/ERK pathway in neonatal mice.

Bioengineered
2021

Microarray and Bioinformatics Analysis of Circular RNA Differential Expression in Newborns With Acute Respiratory Distress Syndrome.

Frontiers in pediatrics
2021

A novel case of neonatal acute respiratory distress syndrome with SARS-CoV-2 infection: potential perinatal transmission.

Archivos argentinos de pediatria
2021

Large difference between Enghoff and Bohr dead space in ventilated infants with hypoxemic respiratory failure.

Pediatric pulmonology
2021

HFOV vs CMV for neonates with moderate-to-severe perinatal onset acute respiratory distress syndrome (NARDS): a propensity score analysis.

European journal of pediatrics
2020

Clarithromycin use for adjunct surgical prophylaxis before non-elective cesarean deliveries to adapt to azithromycin shortages in COVID-19 pandemic.

PloS one
2020

[A single-center retrospective study of neonatal acute respiratory distress syndrome based on the Montreux definition].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2020

Pharmacoeconomic evaluation of different doses of Curosurf for treating neonatal acute respiratory distress syndrome.

Pakistan journal of pharmaceutical sciences
2021

Bovine surfactant in the treatment of pneumonia-induced-neonatal acute respiratory distress syndrome (NARDS) in neonates beyond 34 weeks of gestation: a multicentre, randomized, assessor-blinded, placebo-controlled trial.

European journal of pediatrics
2020

[A clinical epidemiological investigation of neonatal acute respiratory distress syndrome in southwest Hubei, China].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2021

The value of oxygen index and base excess in predicting the outcome of neonatal acute respiratory distress syndrome.

Jornal de pediatria
2020

Venoarterial Extracorporeal Membrane Oxygenation for Severe Neonatal Acute Respiratory Distress Syndrome in a Developing Country.

Frontiers in pediatrics
2020

Surfactant Injury in the Early Phase of Severe Meconium Aspiration Syndrome.

American journal of respiratory cell and molecular biology
2020

Interleukin-37 Attenuates Lipopolysaccharide (LPS)-Induced Neonatal Acute Respiratory Distress Syndrome in Young Mice via Inhibition of Inflammation and Cell Apoptosis.

Medical science monitor : international medical journal of experimental and clinical research
2019

An Unsettled Promise: The Newborn Piglet Model of Neonatal Acute Respiratory Distress Syndrome (NARDS). Physiologic Data and Systematic Review.

Frontiers in physiology
2020

Chlamydia psittaci infection as a cause of respiratory disease in neonatal foals.

Equine veterinary journal
2019

Differences in Clinical Characteristics and Therapy of Neonatal Acute Respiratory Distress Syndrome (ARDS) and Respiratory Distress Syndrome (RDS): A Retrospective Analysis of 925 Cases.

Medical science monitor : international medical journal of experimental and clinical research
2019

Clinical considerations when treating neonatal aspiration syndromes.

Expert review of respiratory medicine
2018

[A review on neonatal acute respiratory distress syndrome].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2018

[Interpretation of Montreux definition of neonatal acute respiratory distress syndrome in 2017].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2018

Overexpressed microRNA-615-3p promotes progression of neonatal acute respiratory distress syndrome by inhibiting differentiation of mesenchymal stem cells to alveolar type II epithelial cells.

European review for medical and pharmacological sciences
2017

Establishing the entity of neonatal acute respiratory distress syndrome.

Journal of thoracic disease

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Dificuldade respiratória aguda neonatal por deficiência de SP-B.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Dificuldade respiratória aguda neonatal por deficiência de SP-B

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Neonatal hypoxic-ischemic encephalopathy online registry in Shenzhen: protocol for a multicentre, prospective, open, observational cohort study.
    BMJ open· 2026· PMID 41857827mais citado
  2. High-Frequency Oscillation vs Mechanical Ventilation for Neonatal Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.
    JAMA network open· 2026· PMID 41801204mais citado
  3. Respiratory Management of Neonatal Acute Respiratory Distress Syndrome.
    JAMA network open· 2026· PMID 41801206mais citado
  4. A Predictive Model for Moderate or Severe Neonatal Acute Respiratory Distress Syndrome in Extremely Preterm Infants with Premature Rupture of Membranes: Development and Internal Validation.
    Journal of inflammation research· 2026· PMID 41798641mais citado
  5. Newborns with ARDS originating from sepsis of extrapulmonary origin exhibit worse prognoses: findings from a multicenter study in China.
    European journal of pediatrics· 2025· PMID 41345740mais citado
  6. The neonatal lung microbiome: a dynamic determinant of respiratory health, disease, and novel therapeutics.
    Front Pediatr· 2026· PMID 41918694recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:217563(Orphanet)
  2. OMIM OMIM:265120(OMIM)
  3. MONDO:0009929(MONDO)
  4. GARD:17126(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Dificuldade respiratória aguda neonatal por deficiência de SP-B
Compêndio · Raras BR

Dificuldade respiratória aguda neonatal por deficiência de SP-B

ORPHA:217563 · MONDO:0009929
Prevalência
Unknown
Herança
Autosomal recessive
CID-10
P28.0 · Atelectasia primária do recém-nascido
CID-11
Ensaios
2 ativos
Início
Neonatal
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C1968602
EuropePMC
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades